16 October 2024 US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity.
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
The US Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), on Friday announced it has selected initial next-generation vaccine candidates and more than $500 million in awards for Project NextGen. 16 October 2023
At its October monthly meeting, the European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval. 14 October 2023
Etrasimod, Pfizer’s oral S1P receptor modulator, has won approval from the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative colitis (UC). 13 October 2023
USA-based CNS disease specialist Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD). 13 October 2023
New data from real-world evidence studies from Anglo-Swedish pharma major AstraZeneca highlight that immunocompromized (IC) individuals continue to face significant and disproportionate burdens from COVID-19. 13 October 2023
US pharma giant Pfizer’s shares dropped 2.5% to close the regular session at $32.11, and fell a further 3.7% to $30.92 in after-hours trading, after it announced significantly changed financial guidance and updated on its government contracts for coronavirus products. 13 October 2023
German eye disease specialist Katairo GmbH today announced top-line results of a multi-national, multicenter, double-masked, placebo-controlled, proof of concept trial to evaluate the safety and efficacy of oral Remofuscin (soraprazen) in adults with Stargardt disease. 12 October 2023
The British medicines regulator has initiated a new scheme designed to reduce the amount of time it takes to approve clinical trials which are deemed to be low risk. 12 October 2023
The US Food and Drug Administration has approved US pharma giant Pfizer’s Braftovi (encorafenib) with Mektovi (binimetinib) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. 12 October 2023
Danish allergy immunotherapy specialist ALK Abello today announced positive top-line results from a Phase III pediatric clinical trial of its sublingual allergy immunotherapy tablet for the treatment of tree-pollen-induced allergic rhinoconjunctivitis. 11 October 2023
A new product from French pharma major Sanofi’s Indian subsidiary, Soliqua (insulin glargine and lixisenatide recombinant fixed-dose combination), has recently been granted approval by the Central Drugs Standard Control Organization (CDSCO). 11 October 2023
Patrick Branch, a Japan-based strategy consultant from LEK Consulting, provides an Expert View on the ‘new map’ for healthcare firms in Asia. 11 October 2023
Swedish company Egetis Therapeutics has raised around $16 million in a private share placement led by US healthcare investor Frazier Life Sciences. 11 October 2023
Danish diabetes care giant Novo Nordisk saw its shares rise 3.7% to 673.90 kroner today, on positive news announced to the stock exchange late on Tuesday. 11 October 2023
Small molecule drugs are carving a significant niche in lung cancer treatment, an area in which AstraZeneca achieved a landmark approval from the US Food and Drug Administration (FDA) following the results of the Phase III AURA trial. 11 October 2023
Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabian Public Investment Fund (PIF), says it has successfully completed its acquisition of a 70% stake in SaudiBio. 11 October 2023
In the USA, the National Institutes of Health has outlined significant new investments to support research into amyotrophic lateral sclerosis (ALS). 10 October 2023
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.